President & CEO
Shunee Yee is the President and CEO of CSOFT International and CSOFT Health Sciences, overseeing operations across 3 continents. In her 25+ years of industry experience, Ms. Yee has been featured in numerous publications, including the Economist, Fortune Magazine, Forbes Asia, and IDG journals. She is also a Fortune selected Top 10 Most Powerful Women Entrepreneur in 2012 and was identified by CNN Money as one of technology’s 36 most powerful disrupters. In June 2016, Ms. Yee helped launch the Shenzhen 100 research report, utilizing qualitative indicators to support global market strategies. Her many contributions in the sphere of education include the Johns Hopkins-Nanjing US-China Center, Michelle Obama’s Let Girls Learn initiative, and her work on the board of trustees at Dexter Southfield School. Additionally, Ms. Yee serves as co-chair for the Joslin Diabetes Center’s A Taste of Ginger 2021 committee, supporting the Asian American Diabetes Initiative (AADI).
Vladimir (Vlado) Misik
VP Global Clinical Trial Strategy at CSOFT Health Sciences
Vladimir (Vlado) Misik brings more than 30 years of biomedical R&D experience into his role of VP Global Clinical Trial Strategy at CSOFT Health Sciences.
After his MSc degree physics and biophysics, and a PhD in biophysics and pharmacology, he worked as a several years as a research scientist in the fields of cardiology, at the School of Medicine at the George Washington University, and oncology, at the National Cancer Institute at the NIH in Bethesda. After his biomedical research scientist tenure, he moved into biopharma product development, including 15+ years at Quintiles/IQVIA in various senior executive roles including VP & Head of Central and Eastern Europe and MENA, and VP of Global Delivery Network. He also served as an executive board member and a CEO at SanaClis, a global full-service specialty CRO. He is a founder/ co-founder of two companies providing services to the clinical research industry: LongTaal, proprietary clinical trials informatics platform, and of VIARES, a clinical research talent organization.
Vlado in an author of > 60 research articles and book chapters in peer-reviewed journals: his current research focus are global geographic trends in industry clinical trials. He serves as an editorial board member at Applied Clinical Research, Clinical Trials, and Regulatory Affairs journal, and is a member of the DIA Core Committee for Clinical Research.
Head Scientific Advisor, CSOFT Health Sciences
Professor Elegant is a physician who joined the pharmaceutical industry after postgraduate training in obstetrics and gynecology in the UK. She has held positions in global drug development, medical affairs, regulatory affairs and drug safety in Japan, Australia, Europe and Asia Pacific. She joined Amgen in October 2016 and is Vice-President, JAPAC Regional Medical Head, based in Hong Kong.
Prior to Amgen, Dr. Elegant was the Vice-President, Regulatory and Medical Affairs, APAC, based in Shanghai for Baxter, and Vice President, Medical Affairs, Asia/ANZ for Baxalta.
Professor Elegant is actively engaged in the training and education of physicians in the healthcare industry. She was involved with establishing the first postgraduate training course for pharmaceutical physicians in Australia. Dr. Elegant is a Fellow of the Faculty of Pharmaceutical Medicine, a member of the FPM International Committee, and is currently working on training programs in the Asia-Pacific region. She is on the Board of Studies for the Masters in Pharmaceutical Medicine, UNSW. She is a founding member of the China Medical Affairs Network. She is on the board of the Medical Affairs Professional Society, and is Adjunct Professor, Faculty of Medicine, University of New South Wales, Sydney Australia.
Professor Elegant is passionate about promoting diversity and inclusion, especially in supporting women leadership. She was involved in Building Talent Edge, a Catalyst Award-winning program supporting women in Baxter Healthcare and leading to a 50:50 men:women ratio at the senior manager level and above across the Asia-Pacific region.
Diego Di Leva
Vice President, Global Operations & Strategic Partnership
Originally from Italy, Diego Di Leva is the VP of Global Language Resources. In this role, Diego leads teams responsible for executing end-to-end project management and supply chain strategy.
He joined CSOFT as an Italian QA Specialist/Translator, position that he covered for five years after which he has started to cover more managerial and operational roles. Prior to joining CSOFT, Diego worked as a Tech Consultant for two years at a leading global mobile company.
Chief Life Science Practice Lead & Executive Director, CSOFT Health Sciences
Di Lv has worked in the international healthcare market for the past 8 years. With a deep understanding of China’s healthcare and regulations, Di received her first law degree in China and then pursued further studies in the UK obtaining a second law degree with a focus in human rights.
Placing high value on continued educational development, she earned a second M.S. degree in management. Entering the healthcare market in 2010, Di first worked in the drug discovery field. Her work took her to Belgium and Germany as a Business Development Manager, calling on clinical institutions, medical schools, and pharmaceutical companies.
Scientific Advisor, CSOFT Health Sciences
Li Chenjian is a principal investigator at the IDG McGovern Institute for Brain Research and Associate Dean of the School of Life Sciences at Peking University. His research in neuroscience and drug development has led to significant insights into the mechanisms of neurodegenerative diseases.
Chief Strategist, China Market Access
With more than 14 years of experience working with international pharmaceutical programs in anti-infective, cardiovascular, endocrine, and nutritional products at companies including Xi‘an Janssen, Novartis Pharmaceuticals, and Mead Johnson (China), Dr. Wang has participated in Asian market registration, clinical research, and market access projects of many important domestic drug varieties.
These projects included: driving the marketing of Zhejiang Whiteson’s Latamoxef (a broad- spectrum beta-lactam antibiotic); facilitating the rapid sales growth (over three years) of Hainan Tianhuang and its nearly 1 billion RMB in revenues after the overall acquisition; assisting Henan Shuaiguang as it became the second company in China to market Clopidogrel there; participating in the formulation of different dose strengths to achieve a greater market success; and indirectly helping Lepu Medical and Gloria Pharmaceuticals to achieve their goals.
Dr. Wang entered the field of translational research in 2013. He headed the Foshan Industrial Technology Research Institute of the Chinese Academy of Sciences’ pharmaceutical project and established strong commercialization partnerships with the Chinese Academy of Sciences and Peking University.
Dr. Wang holds a degree in Pharmacy from the Peking University Health Science Center and was Vice Chairman of the Student Union at the Center.